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ABSTRACT
Objective: The goal of the study was to identify the potential nutrigenetic effects to inulin, a
prebiotic fiber, in mice with different human apolipoprotein E (APOE) genetic variants.
Specifically, we compared responses to inulin for the potential modulation of the systemic
metabolism and neuroprotection via gut-brain axis in mice with human APOE ε3 and ε4 alleles.
Method: We performed experiments with young mice expressing the human APOE3 (E3FAD mice
and APOE4 gene (E4FAD mice). We fed mice with either inulin or control diet for 16 weeks starting
from 3 months of age. We determined gut microbiome diversity and composition using16s rRNA
sequencing, systemic metabolism using in vivo MRI and metabolomics, and blood–brain barrier
(BBB) tight junction expression using Western blot.
Results: In both E3FAD and E4FAD mice, inulin altered the alpha and beta diversity of the gut
microbiome, increased beneficial taxa of bacteria and elevated cecal short chain fatty acid and
hippocampal scyllo-inositol. E3FAD mice had altered metabolism related to tryptophan and
tyrosine, while E4FAD mice had changes in the tricarboxylic acid cycle, pentose phosphate
pathway, and bile acids. Differences were found in levels of brain metabolites related to
oxidative stress, and levels of Claudin-1 and Claudin-5 BBB tight junction expression.
Discussion: We found that inulin had many similar beneficial effects in the gut and brain for both
E3FAD and E4FAD mice, which may be protective for brain functions and reduce risk for
neurodegeneration. . E3FAD and E4FAD mice also had distinct responses in several metabolic







Short chain fatty acids
Introduction
Nutrigenetics refers to the potential impacts of diet that
may be driven by individual’s genetic background [1].
In contrast to the ‘one-size-fits-all’ assumption, it has
been suggested that the heterogeneous response of
gene variants to nutrients and dietary components
may need to be taken into consideration in the nutri-
tional studies [1].
The goal of the study is to understand the nutrige-
netic effects of the Apolipoprotein E gene (APOE) var-
iants to prebiotic inulin. ApoE is a protein involving
cholesterol and lipid transport [2]. Humans possess
three genetic isoforms of APOE – APOE2, APOE3,
and APOE4 – that confer differential risk for develop-
ing metabolic syndrome and neurodegenerative dis-
orders [3]. Specifically, APOE4 carriers have higher
risk than the other two allele carriers for developing
disorders such as diabetes and Alzheimer’s disease
[3]. They show early signs of impairments in mito-
chondrial function, tricarboxylic acid cycle activity,
glucose oxidative metabolism, and cognitive capability
[4,5]. Further, recent studies showed that APOE4 car-
riers are also associated with alternate and imbalanced
gut microbiota (a.k.a., dysbiosis), which in turn exacer-
bates the systemic inflammation and metabolic dys-
function [6–8].
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
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In a previous study, we showed that inulin, a prebio-
tic fiber, is effective in restoring systemic metabolism,
enhancing gut microbiome balance, reducing neuroi-
nflammation, and increasing levels of short chain fatty
acids (SCFAs), tryptophan-derived metabolites, bile
acids, glycolytic metabolites, and scyllo-inositol (inhi-
biting Aβ aggregation) in an APOE4 mouse model
(E4FAD mice) [6]. In this study, our goal is to further
determine if inulin has nutrigenetic effects for mice
with different human APOE variants. In particular, we
wanted to identify if mice with human APOE3 gene
(E3FAD mice; neutral AD risk) would have different
responses to inulin compared to the E4FAD mice.
As APOE4 carriers develop early deficits in brain and
systemic metabolism, it would be important to identity
interventions that may mitigate the deficits at early stage
[4,5]. Therefore, an additional goal of the study was to
determine the effects of inulin as a preventive interven-
tion. We fed young mice (3 months of age) with either
inulin or control diet for 16 weeks. We determined the
effects of inulin on gut microbiome diversity and com-
position, brain and systemic metabolism, as well as
blood–brain barrier (BBB) tight junction expression in
the study.
Methods
Animals and study design
We used a C57BL/6 mouse model which accumulates
human Aβ42 due to co-expression of 5 familial-AD
(5xFAD) mutations in conjunction with human tar-
geted replacement APOE (ε4 in the E4FAD line and ε3
in the E3FAD line). Each mouse was genotyped by
Transnetyx Inc. (Cordova, TN, USA) to verify the gen-
otype after weaning. The mice were separated into 4
groups: E3FAD-control, E3FAD-inulin, E4FAD-con-
trol, and E4FAD-inulin. We determined the sample
size via power analysis with a comparison at a 0.05
level of significance and a 90% chance of detecting a
true difference of each measured variable between
groups; N = 15 per group (male = 7; female = 8) for gut
microbiome experiments, a subset of mice (N = 8/
group; male: female = 1:1) for the brain imaging and
SCFAs experiments, and the other subset of mice
(N = 7/group) for the BBB tight junction measurements.
The prebiotic inulin diet contained 8% of fiber from
inulin, and the control diet contained 8% of fiber from
cellulose (Table 1). We started to feed mice at 3 months
of age and fed them for 16 weeks (till they reached 7
months of age). As we previously reported that the
mice had not developed severe AD pathology nor cogni-
tive impairment at 7–8 months of age [6], the feeding
period allowed us to determine the effects of inulin on
systemic metabolism as a preventive intervention.
Both the inulin diet and the control diet are modifi-
cations of TestDiet’s AIN-93G Semi-Purified Diet
57W5 (cellulose:9GLK; inulin:9GLL). Details of the
composition of the control (cellulose) and inulin diets
can be found in Table 1. Evidence shows that 8% inulin
increases short chain fatty acids and improves enzyme
activity in the mouse cecum compared to 4% inulin
[9]. In addition, studies indicate that 8% inulin intake
(40 g fiber per day) is the maximum amount for western
humans to tolerate without side effects [10]. Each mouse
was single housed (to avoid feces exchange) with ad libi-
tum access to food and water. Food intake and body
weight were recorded biweekly. The study was approved
by the Institutional Animal Care and Use Committee
(IACUC) at the University of Kentucky (UK).
Fecal sample collection and gut microbiome
analysis
Fecal DNA amplification
Fecal samples were collected from all the mice (N = 15/
group) and frozen at −80̊C until further use. A Power-
Soil DNA Isolation Kit (MO BIO Laboratories, Inc.) was
used for fecal DNA extraction, according to the manu-
facturer’s protocol [11]. First stage amplifications were
performed followed by the second-stage PCR amplifica-
tion with Access Array Barcode Library for Illumina
Sequencers (Fluidigm, South San Francisco, CA; Item#
100-4876) at the University of Illinois at Chicago
Sequencing Core. Sequencing was performed at the
W.M. Keck Center for Comparative and Functional
Genomics at the University of Illinois at Urbana-Cham-
paign. The gene amplicon sequence data generated as
part of this study have been submitted to the NCBI Bio-
Project database (PRJNA540508).
Microbial analysis
Forward and reverse reads were merged using PEAR
[12]. Sequences were then trimmed based on quality
scores using a modified Mott algorithm with PHRED
quality threshold of p = 0.01, and sequences shorter
than 300 bases after trimming were discarded. QIIME
v1.8 was used to generate OTU tables and taxonomic
Table 1. Diet composition.
Diet Prebiotic Diet Vehicle Control Diet
Protein % 18.2 18.2
Carbohydrate % 67.8 60.2
Fat % 7.1 7.1
Fiber % 8.0 (Inulin) 8.0 (Cellulose)
Energy (kcal/g) 4.08 3.78
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summaries for all phyla, classes, orders, families, genera,
and species present in the dataset [13]. Shannon and
Bray–Curtis indices were calculated with default par-
ameters in R using the vegan library [14]. The rarefied
species data, taxonomic level 7, were used to calculate
both indices. Significant difference among tested groups
was determined using the Kruskal–Wallis one-way
analysis of variance. The group significance tests were
performed on the rarefied species data, taxonomic
level 6 (genus), using the group_significance.py script
within the QIIME v1.8 package.
In vivo brain metabolites measurements
1H-MRS was conducted on a 7 T ClinScan MR scanner
(Siemens, Germany) at the Magnetic Resonance Ima-
ging & Spectroscopy Center of UK. MRS was utilized
to measure metabolites in the hippocampus, as we pre-
viously reported [6]. N = 8 per group (male: female=1:1)
were used for the experiment. The following metabolites
were measured: alanine, total choline, glutamate-
glutamine complex, myo-inositol, scyllo-inositol, lac-
tate, NAA, phosphocreatine, total creatine, and taurine
using the LCModel software to find the absolute con-
centration of the metabolites [15].
Short chain fatty acid analysis
After euthanizing the mice, we collected cecal and whole
blood samples and sent them to Metabolon Inc. (Durham,
NC) for SCFAs analysis. The same group of mice from the
1H-MRS study (N = 8/group) were used for the exper-
iment. The unit of cecal samples was μg/g and the unit
of blood samples was ng/mL. Samples were processed by
liquid chromatography/mass spectrometry (LC-MS/MS)
for acetate, propionate, and butyrate. Samples were labeled
with internal standards and homogenized in an organic
solvent. They were then centrifuged followed by an aliquot
of the supernatant used to derivatize to form SCFAs
hydrazides. This reaction mixture was subsequently
diluted, and an aliquot was injected onto a C18 column
in Agilent 1290 UHPLC interfaced to an AB Sciex
QTrap 5500 LCMS/MS system with electrospray ioniz-
ation operating in negative mode using electrospray ioniz-
ation. The raw data were analyzed by AB SCIEX software
(Analyst 1.6.2).
Non-targeted metabolomics profiling
The whole blood and brain tissue (from cortex and hip-
pocampus) were processed for metabolomics profiling
at Metabolon Inc. as well. Metabolon’s standard solvent
extraction method was used to prepare the samples,
which were then equally split for analysis via LC/MS
or gas chromatography/mass spectrometry (GC/MS)
using their standard protocol [16]. Non-targeted




Brain capillaries were isolated from another subset of
mice (N = 7/group) as described previously [17]. Iso-
lated capillary pellets from each group were resus-
pended in CelLyticTM lysis buffer (Millipore-Sigma)
containing cOmpleteTM protease inhibitor cocktail
(Roche, Mannheim, Germany). Suspensions were hom-
ogenized, centrifuged (30,000 g for 30 min; 95,000 g for
2h; 4 °C) in a fixed-angle rotor (TLA 100.2; Beckman
Coulter, Indianapolis, IN, USA), resuspended and fro-
zen at −20°C until further analysis.
Western blotting
Sample protein concentrations were determined by
Bradford assay. Membranes were blocked and incu-
bated with primary antibody overnight (β-actin: 1 mg/
ml, ab8226, Abcam, Cambridge, MA, USA; Claudin-1:
0.5 mg/ml, ab56417, Abcam, Cambridge, MA, USA;
Claudin-5: 0.5 mg/mL, 35-2500, Thermo Fisher Scien-
tific; Occludin: 0.5 mg/mL, 71-1500, Thermo Fisher
Scientific). Membranes were washed and incubated
with horseradish peroxidase-conjugated ImmunoPur-
eTM secondary IgG (1:10,000; Pierce, Rockford, IL,
USA) for 1 h at room temperature. Protein bands
were visualized using Pierce SuperSignalTM West Pico
and West Femto chemiluminescent substrates (Thermo
Fisher Scientific) using a ChemiDocTM XRS imager
(Bio-Rad Laboratories, Hercules, CA, USA). Optical
density was measured with ImageLab software (v.4.6.9;
Bio-Rad Laboratories). Four replicate blots were
obtained from pooled tissue of the seven mice in each
group.
Statistical analysis
All statistical analyses were completed using GraphPad
Prism (GraphPad, San Diego, CA, USA). We performed
a 2-way ANOVA to determinate the differences between
groups. To determine which comparison the statistical
differences were coming from we used post hoc Tukey’s
multiple comparisons test. For Metabolon, log trans-
formations were conducted followed by ANOVA for
identification of biochemicals that were significantly
different between groups. Between group differences
were assessed with p-values and q-values (with the
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Benjamini Hochberg FDR) with a p-value or q-value
(when applicable) less than 0.05 showing statistical
significance.
Results
Inulin maintains bodyweight but alters the gut
microbiome of the E3FAD and E4FAD mice.
We first determined if the inulin diet changed the food
intake and bodyweight of the mice compared to the con-
trols. We found that there was no difference in either
food intake (Figure 1A) or body weight (Figure 1B)
between the inulin- and the control-fed mice after 16
weeks of feeding. We further looked at the gut micro-
biome and found that there was a significant decrease
in α-diversity in E3FAD-inulin mice (Gausian link func-
tion results, p < 0.001) (Figure 1C) and in E4FAD-inulin
mice compared to their controls (Gausian link function
results, p = 0.019) (Figure 1D). This shows species rich-
ness and evenness were decreased within each group
following inulin treatment. Similarly, E3FAD- and
E4FAD-inulin mice had significant differences in beta-
diversity compared to the controls (E3FADmice: ANO-
SIM R statistic = 0.877, p-value = 0.001) (Figure 1E)
(E4FAD mice: ANOSIM R statistic = 0.454, p-value =
0.001) (Figure 1F). This shows the ratio of species was
different between the two groups following inulin
treatment.
Significant changes were also observed in numerous
bacterial taxa due to the beneficial effects of the prebio-
tic inulin. Table 2 shows the fold change between the
Figure 1. Food intake and body weight and Gut microbiota diversity. Inulin feeding did not change the (A) food intake and (B)
body weight of the mice. Inulin induced significant differences of the α-diversity in the (C) E3FAD and (D) E4FAD mice, compared to
their control littermates. Inulin also induces significant differences in β -diversity in the (E) E3FAD and (F) E4FAD mice, compared to
their controls. N = 15/group. Data are presented as Mean ± SEM.
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group comparison; red indicates significant increases
while green indicates significant decreases (p < 0.05).
Both E3FAD-inulin and E4FAD-inulin mice had
decreased Turicbacter, but increased Lactobacillus and
Prevotella, compared to their respective control groups.
Moreover, inulin increased Bifidobacterium in E3FAD
mice compared to its control. These results indicate
that the prebiotic inulin alters the gut microbiota in
E3FAD and E4FAD mice in a different manner.
Inulin increased SCFAs in E3FAD and E4FADmice.
Both E3FAD-inulin and E4FAD-inulin mice showed a
significant increase in SCFAs levels in the cecum,
including acetate (Figure 2A), propionate (Figure 2B),
and butyrate (Figure 2C). In the blood samples, we
found that acetate (Figure 2D) was also significantly
higher in the E4FAD-inulin group. Blood propionate
(Figure 2E) and butyrate (Figure 2F) were trending
higher in the Inulin-fed groups though did not reach
statistical significance.
Inulin altered systemic metabolism differently in
the E3FAD and E4FAD mice
From the blood samples, we found that inulin induced
different patterns of metabolic changes among the
Table 2. Gut microbiota taxonomy changed by inulin.
Taxonomic differences at the genus level between E3FAD and
E4FAD prebiotic and control fed mice. q-values were
calculated for each taxon along with each group with a
significant difference (q < 0.05). Fold change was calculated
for each taxon of each group. Red and green shaded cells
indicate p≤ 0.05 (red specifies that the mean values are
significantly higher for that comparison; green values
significantly lower).
E3FAD E4FAD






Turicibacter −2.11 2.96E-06 −0.47 0.03
Lactobacillus +1.21 9.69E-04 +1.48 0.02
Prevotella +1.48 1.11E-03 +1.78 2.17E-03
Bifidobacterium +2.10 2.20E-06 0.11 0.95
Figure 2. Short chain fatty acids (SCFAs). Inulin significantly increased (A) cecal acetate, (B) cecal propionate, and (C) cecal butyrate
of the E3FAD and E4FAD mice compared to their controls. For SCFAs in the blood, significantly elevation was found in (D) acetate from
the E4FAD-inulin group; (E) blood propionate or (F) blood butyrate did not show changes in either of the E3FAD or E4FAD mice. N = 8/
group. Data are Mean ± SEM; ns = not significant (p≥ 0.05), *p < 0.05, **p < 0.01.
NUTRITIONAL NEUROSCIENCE 5
E3FAD and E4FAD mice. Inulin increased tryptophan-
related metabolites while decreasing tyrosine-related
metabolism in the E3FAD-inulin compared to the
E3FAD-control mice (Table 3). The tryptophan metab-
olites included indoleacrylate, indolepropionate (IPA),
serotonin, indoleacetylglycine, and N-acetyltryptophan.
Tyrosine metabolites included phenol sulfate, phenol
glucuronide and p-cresol glucuronide. In the E4FAD-
inulin mice, only changes in indoleacrylate, IPA and
p-cresol glucuronide were seen compared to the
E4FAD-control mice.
In contrast, E4FAD-inulin mice had significant
changes in metabolism involved in the pentose phos-
phate pathway, TCA cycle, and primary and secondary
bile acids. Table 3 shows that E4FAD-inulin mice had
significantly increased levels of ribose, ribitol, ribonate,
ribulose, arabitol, arabonate, and sedoheptulose in pen-
tose metabolism compared to E4FAD-control. In TCA
Cycle metabolites, riboaconitate, isocitric lactone,
succinate, fumarate, and malate increased in the
E4FAD-inulin mice. Inulin also increased bile acid
and their associated metabolites in E4FAD-inulin mice
compared to E4FAD-control mice, including cholate
and beta-muricholate (primary bile acids), and deoxy-
cholate, ursodeoxycholate, 7-ketodeoxycholate and
ursocholate (secondary bile acids). On the other hand,
in the E3FAD-inulin mice, we found increases only in
ribose (pentose metabolism) and alpha-ketoglutarate
(TCA cycle) compared to the E3FAD-control mice.
Inulin changes brain metabolites in the E3FAD
and E4FAD mice
We further looked at the effect of the inulin on brain
metabolites. We found that inulin reduced the level of
5-hydroxyindoleacetate in E4FAD-inulin mice, but not
in the E3FAD mice (Figure 3A). Inulin increased acetyl-
carnitine (C2) concentration in the inulin-fed groups,
though only reached statistical significance in the
E3FAD-inulin group (Figure 3B). In contrast, myo-ino-
sitol concentration decreased in the inulin-fed mice, but
only reached statistical significance in the E4FAD-inulin
mice (Figure 3C). Scyllo-inositol level increased in both
E3FAD-inulin and E4FAD-inulin mice compared to
their controls (Figure 3D). The increase in scyllo-inosi-
tol from the brain tissue was confirmed by in vivo brain
imaging using 1H-MRS. Figure 3E shows the voxel that
was used for obtaining the spectra. We observed the
level of scyllo-inositol to be significantly higher in the
hippocampus in both E3FAD- and E4FAD-inulin
mice relative to their controls (Figure 3F).
Inulin has differential effects on blood–brain
barrier tight junction protein levels in the E3FAD
and E4FAD mice
We have previously reported that dietary inulin reduces
neuroinflammation in the E4FAD mouse model [6]. To
examine the effect of inulin on the brain microvascula-
ture, we compared tight-junction protein expression
levels in brain capillaries isolated from E3FAD-control
and E4FAD-control mice with E3FAD-inulin and
E4FAD-inulin mice (Figure 4A). Inulin did not signifi-
cantly alter occludin protein levels in E3FAD mice or
E4FAD mice but occludin protein levels were signifi-
cantly lower in E4FAD-inulin mice compared to
E3FAD-control mice (p = 0.0045) (Figure 4B). Further,
Claudin-1 protein expression levels were significantly
higher in E4FAD-control mice compared to E3FAD-
control mice (p = 0.0012) (Figure 4C). Inulin did not
alter Claudin-1 protein expression levels in E3FAD
mice whereas Claudin-1 levels were significantly lower
Table 3. Tryptophan and tyrosine metabolism, Pentose
metabolism, TCA cycle, and bile acid changes induced by
inulin. A table showcasing the metabolite changes in
tryptophan and tyrosine metabolism, pentose metabolism,
TCA cycle, and bile acid metabolism due to the prebiotic
inulin and differences and differences between E3FAD and
E4FAD mice in the blood. Welch’s two-sample t-test was
performed. Heat map of statistically significant biochemicals
profiled when comparing groups are labeled as follows: Red
and green shaded cells indicate p≤ 0.05 (red specifies that
the mean values are significantly higher for that comparison;




Pathway Biochemical Name E3FAD E4FAD





Tyrosine Metabolism phenol sulfate 0.23 0.87
phenol glucuronide 0.21 2.11
p-cresol glucuronide 0.08 0.14












Primary Bile Acid Metabolism cholate 1.06 10.92
beta-muricholate 1.82 16.81
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in E4FAD-inuiln mice compared to E4FAD-control
mice (p = 0.0036). E3FAD-inulin mice also had a signifi-
cantly higher protein expression for Claudin-5 com-
pared to E3FAD-control mice (p = 0.0122) (Figure
4D). Likewise, Claudin-5 protein expression levels
were significantly higher in E3FAD-control mice com-
pared to E4FAD-inulin mice (p = 0.0026). These values
indicate that inulin affects tight-junction proteins differ-
ently in E3FAD and E4FAD mice.
Discussion
In this study, we demonstrated that inulin had systemic
benefits for both E3FAD and E4FAD mice. We further
demonstrated that the E3FAD and E4FAD mice had
very different responses to inulin, indicating a nutrige-
netic effect depending on APOE genotype. Figure 5
summarizes the similarities and differences of E3FAD
and E4FAD mice responding to inulin.
The similar effects that inulin had on E3FAD and
E4FAD mice included the alpha- and beta- diversity
of the gut microbiome, increased the abundance of
Lactobacillus and Prevotella taxa, and reduced abun-
dance of Tuicibacter taxa (Figure 5; middle column).
In both groups, inulin also increased the cecal SCFAs
and scyllo-inositol level in the hippocampus. Lactoba-
cillus and Prevotella are known to produce SCFAs
including acetate, butyrate, and propionate [18–20].
This is consistent with our findings that SCFAs were
increased in the inulin-fed mice, specifically acetate
in the E4FAD mice. Though present mostly in the per-
ipheral system [21,22], SCFAs have been shown to
have a dramatic impact on brain vascular and meta-
bolic function [23]. Specifically, butyrate was shown
to be able to restore BBB tight junctions and conse-
quently restored BBB function [24], which is consistent
with our results of changes in Claudin-5 expression in
the BBB of E3FAD mice. Further, scyllo-inositol was
found to be increased in the hippocampus in vivo
and from the brain extracts. Scyllo-inositol has been
shown to inhibit Aβ42 aggregation in both animal
and clinical trials [25,26], suggesting that inulin
might be able to reduce AD pathology when the mice
get older.
Figure 3. Metabolite changes in brain tissue in response to inulin and Scyllo-inositol levels in the hippocampus, fecal cul-
ture, and plasma. (A) 5-hydroxyindoleacetate was reduced in the E4FAD-inulin mice compared to the E4FAD-control. (B) Acetylcar-
nitine (C2) was increased in the E3FAD-inulin mice compared to E3FAD-control. (C) Myo-inositol was significantly lower in the
E4FAD-inulin mice compared to the controls. (D) Scyllo-inositol was elevated in both E3FAD-inulin and E4FAD-inulin mice compared
to their controls. (E) 1H-MRS voxel on hippocampus. (F) Scyllo-inositol was dramatically increased in the hippocampus of E3FAD-inulin
and E4FAD-inulin mice compared to E3FAD-control and E4FAD-control mice, respectively. N = 8/group. Data are Mean ± SEM, ns = not
significant (p≥ 0.05), *p < 0.05, **p < 0.01, ****p < 0.0001.
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Figure 4. Western blot analysis of tight-junction protein expression levels. (A) Representative Western blot for Occludin (∼55-
65 kDa), Claudin-1 (∼23 kDa), and Claudin-5 (∼23 kDa). β-actin (∼42 kDa) served as protein loading control. Normalized protein
expression levels for (B) Occludin, (C) Claudin-1, and (D) Claudin-5 are given as fold change in percent (%). Values are represented
as Mean ± SEM for replicate blots (N = 4; pooled tissue from E3FAD-Control (N = 7 mice), E3FAD-Inulin (N = 7 mice), E4FAD-Control
(N = 7 mice), E4FAD-Inulin (N = 7 mice); *p < 0.0332; ** p < 0.0021; ***p < 0.0002.
Figure 5. Summary of the similarities and differences of responses to inulin between E3FAD and E4FAD mice.
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Inulin induced different responses between the
E3FAD (Figure 5, left column) and E4FAD mice
(Figure 5, right column). Notably, E3FAD mice had
altered metabolic pathways in the periphery related to
tryptophan and tyrosine, while E4FAD mice had
changes related to TCA, PPP and bile acids. Inulin
increased Bifidobacterium in the E3FAD mice but
showed no change in the E4FAD mice. There were
also different changes in brain metabolites, and levels
of Claudin-1 and Claudin-5 expressions between the
two groups.
Tryptophan and tyrosine metabolism are known
to enhance the nervous system. Tryptophan is an essen-
tial amino acid and is the precursor of
serotonin and indole-3-propionic acid, a tryptophan-
derived metabolite, can inhibit Aβ fibril formation in
neurons and neuroblastoma cells [27]. Metabolites that
play a role in tyrosine metabolism including phenol sul-
fate, phenol glucuronide, and p-cresol glucuronide were
found to be lower in the inulin-fed mice, suggesting that
inulin decreases inflammation in the E3FAD mice [28].
The higher abundance of Bifidobacterium found in the
E3FAD mice compared to E4FAD mice suggests a
reduced level of anxiety [29], which is consistent with
our previous findings that E3FAD mice had lower
anxiety compared to the E4FAD mice [30]. In contrast,
E4FAD mice had enhanced TCA, PPP and bile acid
metabolism compared to E3FAD mice. Both TCA and
PPP pathways involve energy production through mito-
chondria [31]. Research shows that the PPP regulates the
chronic neuroinflammation in the brain and may thera-
peutically improve neurodegeneration in the brain such
as Parkinson’s disease [31]. Further, bile acids signifi-
cantly impact pathways involved in host cholesterol,
lipid and glucose metabolism, and inflammation, and
have the potential to alter the host immunity [32] and
circadian rhythms [33]. Collective evidence also shows
that primary and secondary bile acid metabolism regu-
lates the innate immune system by activation of bile
acid activated receptors [34] and adaptive immune sys-
tem by regulation of Th17 cells and regulatory T cells
[35]. These findings are consistent with neuroimaging
markers, showing that E4FAD mice had decreases in
myo-inositol [36,37], an inflammatory marker, in the
hippocampus.
In brain metabolites, we found increased acetylcarni-
tine in E3FAD-inulin mice. Acetylcarnitine has been
well studied to prevent oxidative stress and aging [38],
suggesting inulin may reduce oxidative stress for the
E3FAD mice. In contrast, we found reduced 5-hydro-
xyindoleacetate in the E4FAD-inulin mice. 5-hydro-
xyindoleacetate has been shown to be related to
aggressive behaviors and toxification by affecting brain
glutathione-S-transferase [39,40]. Therefore, inulin
might benefit the E3FAD mice by oxidative stress
reduction, while it might benefit the E4FAD mice by
increasing detoxification in the brain and lowering the
risk for aggressive behavior development.
Previous studies found that the ApoE4 genetic back-
ground is associated with BBB dysfunction [41]. In the
present study, we observed that inulin differentially
affects tight-junction protein expression levels in iso-
lated brain capillaries from E3FAD and E4FAD mice.
Specifically, inulin decreased Claudin-1 expression in
E4FAD mice, while increasing Claudin-5 expression in
E3FAD mice. A previous study in a chronic stroke
mouse model showed that increased Claudin-1 protein
expression is associated with leaky brain capillaries
and an endothelial proinflammatory phenotype [42].
Claudin-5 is the most enriched tight junction protein
and its dysfunction has been implicated in many neuro-
logical disorders including AD, multiple sclerosis,
depression, and schizophrenia [43]. It is possible to
abrogate disease symptoms in many of these disorders
by regulating levels of Claudin-5.
Though we studied the mice at pre-symptomatic
stage, our study implies that inulin may reduce risk
for developing AD for both APOE3 and APOE4 carriers.
Emerging evidence further shows that AD is associated
with brain metabolic impairment [44], gut microbiota
dysbiosis [45], and bile acid profile alterations [46].
Further, tryptophan metabolism is also seen to be
altered in patients with AD [47], which impedes the
capacity to inhibit Aβ fibril formation in neurons and
neuroblastoma cells [27]. The findings from the current
studies suggest that AD risk might be able to be miti-
gated with early interventions of inulin. Future studies
will be needed to verify the speculation with older
animals.
In summary, we demonstrated that early interven-
tions of inulin would be beneficial for enhancing brain
and systemic metabolism through gut-brain axis, and
the responses to the inulin diet are APOE genotype-
dependent. Our findings indicate the importance of
nutrigenetics and precision nutrition as the responses
to a diet may be highly dependent on the genotype of
the host.
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